The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1549
ISSUE1549
June 18, 2018
Andexxa - An Antidote for Apixaban and Rivaroxaban
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Andexxa - An Antidote for Apixaban and Rivaroxaban
June 18, 2018 (Issue: 1549)
Coagulation factor Xa (recombinant), inactivated-zhzo
(andexanet alfa; Andexxa – Portola) has received
accelerated approval from the FDA for urgent reversal
of the anticoagulant effect of the direct factor Xa
inhibitors apixaban (Eliquis) and...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.